Cristina Suárez discusses additional efficacy findings, including data from the sarcomatoid subgroup, and quality of life results from the CheckMate 9ER trial of first-line nivolumab plus cabozantinib in patients with advanced renal cell carcinoma.
View more from the 2021 Genitourinary Cancers Symposium on Medicine Matters oncology: [ Ссылка ]
